Clinical Trial Update: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial THRIVE-2 evaluating Veligrotug (VRDN-001) for chronic Thyroid Eye Disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thyroid Eye Disease

Drugs mentioned

• Veligrotug (VRDN 001)

Snippet

Sponsor: Viridian Therapeutics, Inc. | Conditions: Thyroid Eye Disease | Phase 3 | Status: COMPLETED